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Pretreatment levels of urinary deoxypyridinoline as
a potential marker in patients with prostate cancer
with or without bone metastasis
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H.J .A. MENSINK§
Departments of Urology, †Nuclear Medicine, ‡Radiology and "Clinical Chemistry, Martini Hospital, and the Departments of
*General Practice and §Urology, University Hospital, Groningen, The Netherlands
Objective To assess the predictive role of the bone
markers alkaline phosphatase (ALP) and urinary
deoxypyridinoline (DPD), as indicators of bone turn-
over, at baseline in patients with prostate cancer.
Patients, subjects and methods Urinary DPD, serum ALP
and prostate-specific antigen (PSA) were evaluated in
23 patients with benign prostatic hyperplasia (BPH),
115 with prostatic carcinoma, of whom 21 had bone
metastasis, and in 16 age-matched control subjects.
Results Patients with newly diagnosed prostate cancer
and bone metastasis had a higher urinary excretion of
DPD, and a higher serum PSA and ALP than had
patients with BPH and those with prostate cancer but
no metastasis. Receiver operating curve analysis for
PSA, ALP and DPD showed a significant discriminat-
ing ability for positive and negative bone scans
(P=0.0684). However, from logistic regression of
the combinations, only serum ALP was a significant
independent predictor of bone metastasis in patients
with prostate cancer.
Conclusion Serum ALP or urinary DPD are the best
predictors of bone metastasis in patients with prostate
cancer; further studies with more patients are
required.
Keywords prostate cancer, bone metastasis, serum
prostate-specific antigen, alkaline phosphatase, urin-
ary deoxypyridinoline
Introduction
In many Western countries prostate cancer is the second
most common cause of cancer death in men, and the
incidence is increasing [1,2]. At initial presentation 40%
of patients with prostate cancer have bone metastases [3];
these are predominantly osteoblastic. Bone is a dynamic
structure and constantly in a state of turnover, a
metabolic process termed remodelling. This includes
degradation (bone resorption) mediated by the action of
osteoclasts, and building (bone formation), mediated
by the action of osteoblasts. Remodelling is required
for the maintenance and overall health of bone, and is
tightly coupled. In normal bone there is a constant
balance between bone formation and bone resorption.
In abnormal situations of bone metabolism this process
becomes uncoupled and, when resorption exceeds
formation, results in a net loss of bone.
The introduction of new biochemical markers of bone
metabolism has revealed various aspects of benign and
malignant bone diseases. Of the organic matrix in bone,
< 90% contains type 1 collagen, a triple helical protein
[4]. Type 1 collagen of bone is cross-linked by specific
molecules that provide rigidity and strength. Crosslinks
of mature type 1 collagen in bone are the pyridinium
crosslinks, pyridinoline and deoxypyridinoline (DPD) [5].
DPD is formed by the enzymatic action of lysyl oxidase on
the amino-acid lysine, is released into the circulation
during the bone resorption process and represents, to a
greater or lesser extent, the activity of metastases. DPD is
excreted unmetabolized in urine; its uptake is unaffected
by diet [6], allowing a suitable assessment of resorption.
Urinary DPD concentration has been used to estimate
the degree of bone resorption. In the present study
we investigated the utility of PSA, alkaline phosphatase
(ALP) and urinary DPD as markers of bone metastasis
in patients with prostate cancer.
Patients, subjects and methods
The study group comprised 138 men, referred to the
urological outpatient clinic and who provided informed
consent. Exclusion criteria were; bone, endocrine or
chronic disorders, the use of medication known toAccepted for publication 18 April 2001
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influence bone metabolism (e.g. corticosteroids, GnRH
analogues, anticonvulsants, thyroid medications or
heparins). Patients in the study group had BPH or
prostate cancer, the latter being clinically confined to the
prostate (T1–2) or locally advanced (T3–4) or with bone
metastases.
Patients with prostate cancer underwent bone scinti-
graphy to diagnose or exclude bone metastasis; 3–4 h
after an intravenous injection with 700 MBq 99mTc-
methylene diphosphonate, anterior and posterior
whole-body images were obtained. Detailed images
were acquired when considered necessary. According
to the bone-scan results, the patients were divided into
those with or with no bone metastases.
The control group of men, in which only DPD and
creatinine were measured in the urine, comprised 16
presumably healthy young men aged 20–50 years. As
these men were not part of a screening programme, no
DRE or other laboratory results were known.
The level of serum PSA and ALP was determined in all
patients. Blood samples were collected using a standard
venipuncture technique and serum separated after
centrifuging blood at 4uC and 1500 g for 10 min;
samples were then stored at x20uC until analysis.
Urine samples for the determination of DPD crosslinks
were obtained from the first or second morning void,
collected on the day of the bone scan. In the control
group the urine samples were collected within 2 weeks of
their outpatient department visit. The urine specimens
were immediately frozen at x20uC. The concentration of
DPD was expressed relative to the concentration of
urinary creatinine (mmol/mol creatinine) to control for
differences in body mass and urine dilution.
Serum ALP was analysed according to the manufac-
turer’s instructions on a Synchron LX 20 autoanalyser
and reagents (Beckman Coulter Instruments Inc.,
Fullerton, CA, USA); the reference value for normal
subjects is 40–130 U/L.
PSA in serum was determined using a chemilumines-
cent assay on an Immulite 2000 automatic immunoas-
say system, according to the manufacturer’s instructions
(DPC, Breda, The Netherlands); the threshold value used
was 4 mg/L.
The urinary concentration of free deoxypyridinoline
was determined using a chemiluminescent enzyme
immunoassay according to the manufacturer’s instruc-
tion (Immulite Pyrilinks-D, a solid-phase, chemilumines-
cent enzyme immunoassay for use with the Immulite I
Automated Analyser, and designed for the quantitative
measurement of DPD in urine; DPC). The normal
reference range for urinary DPD (normalized to creati-
nine level) was 2.3–5.4 nmol/mmol creatinine. Urinary
creatinine concentrations were determined using the
Jaffe rate method (Synchron LX 20).
All analyte levels are presented as the median (range),
with the significance of differences between the control
and the different groups of patients assessed using the
Mann–Whitney U-test, and P<0.05 considered to
indicate statistical significance. The relative effectiveness
of the diagnostic tests was assessed by plotting the true-
positive (sensitivity) vs false-positive (1-specificity) ratios
on a ROC curve. This analysis is particularly useful for
comparing two diagnostic tests when the threshold for a
positive or negative test has not been clearly defined.
Areas under the ROC curve were compared. To evaluate
the independent contribution of PSA, ALP and DPD in
predicting bone metastasis, correlation coefficients were
calculated, and followed by logistic regression analysis.
For this analysis all values were transformed onto a
logarithmic scale and linear regression analysis used,
with P<0.05 considered significant.
Results
Twenty-three patients had clinically diagnosed BPH,
later confirmed pathologically from TURP material; 115
patients had prostate cancer, histologically confirmed
after biopsy and/or surgery (TURP, open prostatectomy
or radical prostatectomy). The characteristics of the
patients are shown in Table 1. The patients with BPH had
normal values of PSA and, as expected, those with
prostate cancer had an elevated PSA level. The median
PSA level differed significantly between patients with and
with no bone metastasis, although there was some
overlap in the PSA values between the groups.
Table 1 also gives the values of ALP and DPD for the
three patient groups and the controls. The urinary
excretion of DPD relative to creatinine and serum ALP
was significantly greater in the 21 patients with bone
metastasis than in those with BPH or with no bone
metastasis (P<0.001). The urinary excretion of DPD was
similar in the last two groups. Similarly patients with
prostate cancer and bone metastasis had a significantly
higher level of PSA (P<0.001) and ALP (P<0.001) than
those with no metastasis (Table 1).
The relative effectiveness of PSA, ALP and DPD/
creatinine in urine for discriminating between T3–4
prostate cancer with and without bone metastasis is
shown in the ROC curves (Fig. 1). The sensitivity
appeared to be comparable, at 0.643 for PSA, 0.792
for DPD/creatinine and 0.815 for ALP. The relationships
among PSA, ALP and DPD in patients with prostate
cancer are shown in Fig. 2. Although all correlation
coefficients were significantly positive (P<0.005), the
correlation between PSA and ALP was low (r=0.268,
Fig. 2a), and between PSA and DPD only moderate
(r=0.317, Fig. 2b). The strongest relationship was
between ALP and DPD (r=0.635, Fig. 2c). Logistic
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regression showed that in combination, only ALP had
a significant independent contribution to predicting
the presence of bone metastasis, the odds ratios (95%
CI) being 1.04 (0.685–1.593) for PSA, 5.88 (1.156–
29.873) for ALP and 1.92 (0.460–8.019) for DPD/
creatinine. Table 2 gives the sensitivity, specificity,
positive predictive value, false-positive and false-negative
values for ALP, DPD and PSA at various thresholds for
the individual patients.
Discussion
Bone metastases are a major cause of morbidity in
patients with prostate cancer, causing subsequent
significant clinical problems, including pain and patho-
logical fractures. Therefore detecting bone metastasis
is crucial for the staging, treatment and follow-up of
prostate cancer. Bone scintigraphy, used in the initial
staging and during the follow-up of prostate cancer, has
been the most sensitive but not the most specific method
to detect bone metastasis. ‘Hot spots’ on a bone scan are
not always metastases, but can be associated with benign
1–Specificity












Fig. 1. ROC curves for PSA (red, solid), ALP (light red, dashed) and
DPD (green, dotted) in patients with T3–4 prostatic carcinoma with
and with no bone metastasis. Areas under the ROC curves suggested
that sensitivity for all markers was comparable and not significantly
different from each other.
Table 1 Characteristics of the patient groups and the levels of the markers
Variable BPH
Prostate cancer
ControlsT1–2 T3–4 Bone metastasis
No. of patients 23 46 48 21 16
Median (range)
Age, years 68 (48–87) 73 (52–80) 69 (36–89) 74 (48–91) –
PSA, mg/L 3.05 (0.2–11.5)* 17 (0.5–328)† 39.2 (0.1–1053) 81 (0.74–3063) –
ALP, U/L 75 (43–185) 73 (34–313) 68 (44–204) 152 (29–1190)‡ –
DPD/creatinine, 6.2 (3.94–13.3) 6.0 (1.9–300) 6.3 (4.8–50.0) 14.09 (4.6–300)‡ 4.42 (2.96–6.58)
mmol/mmol
P<0.001, *BPH vs prostate cancer with no metastasis; †prostate cancer with no metastasis vs prostate cancer with metastasis (Mann–Whitney
U-test). ‡Control group vs BPH vs prostate cancer with no metastasis vs prostate cancer with metastasis (Kruskal–Wallis test).
Table 2 Sensitivity, specificity, positive predictive value (PPV), false-positives and false-negatives for ALP, DPD/creatinine and PSA at
various thresholds
Marker/threshold Sensitivity, % Specificity, % PPV, % False-positive, n False-negative, n
ALP (N=69)
60 91 31 37 33 2
80 81 71 55 14 4
100 71 88 71 6 6
DPD/creatinine (N=66)
6 90 37 38 29 2
7 85 57 46 20 3
10 65 83 62 7 8
PSA (N=69)
10 86 13 30 42 3
20 81 21 31 38 4
40 76 50 40 24 5
60 62 69 46 15 8
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diseases, e.g. degenerative changes or trauma. Further-
more, bone scans are expensive and time-consuming.
More sensitive and specific serum markers to discriminate
between patients with and with no bone metastasis
from prostate cancer would be valuable for the clinician,
particularly in the early diagnosis and additional treat-
ment of advanced prostate cancer.
PSA is the most useful marker for determining the
extent of prostate cancer; in patients with a PSA level of
f10 mg/L an initial bone scan is, according to published
studies, usually unnecessary [7,8]. PSA is not specific for
bone metastases and is affected by other metastatic
burdens. Moreover, in poorly differentiated carcinoma,
there is not always a correlation between tumour volume
and the serum PSA value [9]. PSA expression is regulated
by androgen and after hormonal manipulation 34% of
patients have a normal PSA, despite progression of bone
metastasis [10].
In the present study, patients with bone metastasis
had significantly greater levels of DPD in urine than
had patients with no bone metastasis or with BPH
(P<0.001). However, the combination of ALP and
DPD appeared to be the most powerful predictor of
bone metastasis (Table 2). This result refocuses atten-
tion on serum ALP as an important marker of metastatic
disease. Urinary DPD may provide a useful marker to
supplement ALP and PSA in evaluating bone scan results
and the response to hormonal therapy [11,12].
In conclusion, the detection of possible bone metastasis
is essential in the treatment of patients with prostate
cancer. Serum ALP and PSA combined with the assay of
urinary DPD may provide valuable additional indicators
of metastases to the bone in untreated patients, and in
monitoring the efficacy of therapy [11,12]. Additional
studies with more patients and information during the
follow-up are needed.
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Fig. 2. Relationships between a, PSA and ALP (r=0.268), b, PSA
and DPD/creatinine (r=0.317), and c, ALP and DPD/creatinine
(r=0.635). All values are expressed on a logarithmic scale. All
correlation coefficients are significantly different from 0 at
P<0.005.
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